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Abstract 
Background The annual stroke rate in atrial fibrillation is
around 5 per cent with increased risk in those with hyper-
tension, diabetes, left ventricular dysfunction and other
cardiovascular risk factors. This study set out to identify the
patients with atrial fibrillation and modifiable risk factors for
stroke. 
Method Analysis of practice computer data taken from eight
general practices (81 811 patients) in the south of England.
944 patients with a diagnosis of atrial fibrillation, of whom
782 (82.8 per cent) were aged 65 years and over. 
Results The age standardised prevalence of diagnosed atrial
fibrillation was 1.23 per cent (1.28 per cent for men and
1.18 per cent for women). It was much more prevalent in the
older population, 8.28 per cent and 6.66 per cent for males and
females over 65, respectively. Cardiovascular co-morbidities
were more frequent with increasing age. Blood pressure
(BP) was recorded in over 95 per cent of patients with atrial
fibrillation though there was scope for improving control;
25 per cent of men and 31 per cent women had a BP over
150/90. Inconsistent recording of ECG and echocardiography
made it hard to identify patients with left ventricular dys-
function. Forty six per cent of men and 37 per cent of
women were either being prescribed Warfarin, or had con-
traindications to its use; of those on Warfarin 75.9 per cent
have an international normalized ratio in range. Forty four
per cent were treated with aspirin. People at high risk of
stroke were no more likely to be treated with Warfarin or
aspirin than those at moderate risk. 
Conclusions The rate of use of Warfarin remains low, and
there is scope for better recording and management of risk
factors particularly BP. 
Keywords: atrial fibrillation, stroke, hypertension, primary
health care, standards, comparative study 
Introduction 
Atrial fibrillation (AF) is the commonest cardiac arrhythmia
managed in primary care,1 and because it is an important risk
factor for stroke it has significant implications for people with
the condition and for health services.2 The prevalence of AF in
general practice in England and Wales was estimated in 1998 at
12.1 per 1000 in men and 12.7 per 1000 in women with a reported
increase in prevalence since 1994,3 a similar increase has been
reported in the USA.4 Its prevalence increases with age, with
approximately 5 per cent of those over 65, and 10 per cent of
those over 85 years.5,6 The annual rate of stroke with AF is about
4.5 per cent.7 There is consensus that the risk of stroke in people
with AF is greater in those who also have hypertension,8 diabe-
tes, left ventricular dysfunction, or previous cerebrovascular acci-
dent and are older than 65.9,10 Other risk factors which may also
contribute include: smoking, obesity, existing ischaemic heart
disease and hyperlipidaemia,11–13 although modifying these may
result in a lesser reduction in stroke risk in people with AF. How-
ever they are worth addressing as many of these people are at risk
from other cardiovascular diseases as well.14 
Anti-coagulation has been demonstrated to be effective in
reducing the incidence of stroke in patients with AF, with aspirin
providing lesser benefits.15 Many believe that anti-coagulants are
under-utilized, with only around a fifth of patients receiving
them.9,16 One reason for this is the need to regulate Warfarin
therapy strictly to avoid the risk of haemorrhage. Where this
cannot be achieved in this elderly population then aspirin may
provide a safer option;17 though opting for aspirin ahead of
Warfarin remains controversial. Decision making about this
issue is often complex, because many with AF are elderly with
multiple medical problems and therapy.18,19 
In the UK Primary Care Trusts commission care for their
geographical locality. One such trust was interested to examine
the quality of care of patients with AF, and whether they could
be identified by computer searches across a number of practices in
their locality. If this proved feasible then this would allow these
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patients to be identified, and services targeted appropriately.
We therefore conducted this study to see if it was possible to
identify high risk patients, with suboptimally managed AF,
from searches of general practice computer records. 
Method 
This study was carried out in eight general practices, with a total
registered population of 81 811 (range 3559 to 14 834), in a single
locality in the south of England. There are similar numbers of
very elderly, over 85 years. The AF prevalence is age- and sex-
standardised against the England and Wales population.20 
The data were collected between May 2004 and July 2004,
with written consent of the practices and approval of the local
primary care trust. During this period a data collector visited
each practice and collected information on demography,
diagnosis, investigations, and treatment from their computer
systems using the health query language MIQUEST21 (Morbidity
Information and Export Syntax; Box 1). 
The data had to be extensively cleaned and processed. 
Data reliability was tested by careful examination of the
denominator, the diagnostic and other clinical data due to
be used in the study.22,23 This involved creating a graphical
representation of the age-sex profile of each practice; and also
for any diseases that were to be part of the analysis. Recording
levels of numerical variables (e.g. systolic BP) were examined
for, and histograms plotted to observe their distribution.
Recording levels were compared between practices; and if there
were large discrepancies in the data or missing data then the
variable concerned has been excluded from the analysis. The
only exceptions are ECG data and echocardiogram data,
which are specifically included as examples where data quality
is poor. 
Not all practice computer systems use precisely the same cod-
ing system. All these practices were either EMIS (Egton Medical
Information Systems24) or Torex Premiere.25 Both of these use the
Read version 2 5-Byte code set. However, EMIS uses many of its
own codes; and has an entirely independent drug dictionary. The
EMIS drug codes are unique and do not precisely mirror the Read
classification for drugs. We recoded data into classes and prepara-
tions; so that we had a simple numeric variable which for example
indicates whether a patient has been prescribed Warfarin. 
We calculated the prevalence of AF and of cardiovascular
co-morbidities and risk factors by age group and sex. We ana-
lysed in 10 year bands from age 25 upwards, grouping together
the population over 85 years. 
We went on to examine the proportion of people with AF
who had one of the following cardiovascular conditions, ischae-
mic heart disease, heart failure and diagnosis of hypertension and
the proportion of patients with cardiovascular risk factors (blood
pressure, smoking status, BMI and cholesterol levels) recorded
on the practice computer. In addition we identified those with
mitral valve disease and rheumatic fever, and those treated with
an anti-coagulant (Warfarin) and anti-platelet therapy (aspirin). 
We defined current therapy as issue of a prescription in the
last 60 days; as the locality policy was to issue repeat prescrip-
tions for 60 days therapy, though locality representatives said
that they often issued Warfarin prescriptions for shorter periods. 
We then formulated audit criteria (Box 2) based best prac-
tice guidance;26,27 in conjunction with representatives of the
practices involved. It was agreed that cardiovascular risk fac-
tors would be examined using the standards set out in the UK
National Service Framework for Coronary Heart Disease28 and
that the ‘gold standard’ treatment was the current prescription
of Warfarin, unless contraindicated, with an international
normalized ratio (INR) target range of 2–3 for these patients.
Data were analysed in SPSS Version 12. 
Box 1 Data set collected about each person    
Demographic details MIQUEST unique ID, age and sex
Diagnostic data Atrial fibrillation, hypertension, diabetes, 
coronary heart disease, TIA (Transient 
Ischaemic Attack) or stroke, heart failure 
Cardiovascular risk
factors
Blood pressure, BMI, smoking status, 
cholesterol level, electrolytes, ECG 
recording, echocardiogram results, INR 
Drug treatment Warfarin, aspirin, clopidogrel, 
dipyridamole, Digoxin, ACE-inhibitors 
Box 2 Audit criteria     
Co-morbidity 
The percentage of people with AF who have cardiovascular 
co-morbidities recorded,including previous stroke of TIA, 
diabetes and heart failure 
The number of people with mitral valve disease or a history of 
rheumatic fever 
Blood pressure management in AF 
The percentage of people with a blood pressure recorded 
The percentage of people with a blood pressure above the 140/85 
and 150/90 mmHg thresholds 
Left ventricular hypertrophy 
The percentage of people with an ECG or echocardiogram result 
The proportion of these that indicate left ventricular hypertrophy 
Lifestyle in people with AF 
The percentage of people with a smoking habit and BMI recorded 
The proportion of smokers and those with a raised BMI 
Lipids and monitoring of electrolytes 
The percentage of people who have had their cholesterol measured
The achievement of national targets (<5 mmol/l for total cholesterol) 
The percentage with electrolytes recorded, and number with 
hypo or hyperkalaemia or impaired renal function 
Anti-thrombus and anti-coagulant treatment 
The percentage of people with concurrent cardiovascular disease 
who have been offered anti-platelet or anti-coagulant therapy; 
and the proportion where therapy is current (prescribed in the 
last three months) 
Recording of contraindications to aspirin and Warfarin 
Proportion of those currently on Warfarin with an ‘in range’ INR
(2.0–3.0) 
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Results 
In total, there were 944 people with AF an overall prevalence of
11.5 per 1000 patients (Table 1) Prevalence rates increased with
age, from less than 1 per 1000 in people aged under the age of 35
to 96.7 per 1000 in people aged over 75 years. The prevalence was
higher in males than in females in all age categories, with an over-
all prevalence of 12.3 per 1000 males and 10.8 per 1000 females.
941 were aged 25 years and above, those aged below 25 years were
excluded from the further analysis. The age-standardized preva-
lence, using the population of England and Wales, was 12.8 for
males, 11.8 for females and 12.3 per 1000 overall. 
A high proportion of patients had a concurrent cardiovascular
diagnoses (Table 2). Ischaemic heart disease (IHD) was much
more prevalent in men than women (31.6 per cent compared
with 23.7 per cent); diabetes was more common in men (14.5
per cent compared with 11.6 per cent); stroke, heart failure and
hypertension had smaller or no sex differences. 
Cardiovascular risk factor recording was variable (Table 3).
Nearly everybody (98 per cent) had a blood pressure recording
and just under 90 per cent a smoking record. BMI, cholesterol
and LDL-cholesterol were recorded more in men. LDL was
measured in less than half of men (43.1 per cent) and under a
third of women (30.8 per cent). 
Although the mean systolic and diastolic blood pressures,
cholesterol and LDL cholesterol are below the target set for
blood pressure control in national guidance28 (Table 4), this
inevitably leaves a considerable proportion above. 
Fifty seven per cent have a blood pressure at or above the 140/
85 threshold (i.e. either systolic is ≥140 or diastolic ≥85) of whom
28 per cent above 150/90 (Table 5). Approximately 10 per cent of
men and women have cholesterol and LDL above recommended
treatment thresholds; though these figures should be treated with
caution because of the high percentage of patients who have not
had a cholesterol or LDL measure. A total of 24.5 per cent are
recorded as current or ex-smokers. Almost exactly twice as many
men are smokers as women. Perhaps reflecting the relatively
affluent area of Surrey these practices are located in, 63 per cent
are recorded as having never smoked. Just over a quarter of peo-
ple with AF have a BMI over 28. Only 9.5 per cent of people with
AF are recorded as having an ECG, and only 4.5 per cent an
echocardiogram. There is not sufficient data to make valid
comments about left ventricular hypertrophy. 
Anti-coagulant and anti-platelet therapy are prescribed
differently to men and women. Warfarin is prescribed to more
men than women (42.6 per cent, compared with 35.2 per cent).
Table 1 Prevalence of AF recording
Age  
..................................................
Gender  
Total  Female Male 
0–24 0.00% (0) 0.03% (3) 0.01% (3) 
25–34 0.02% (1) 0.05% (3) 0.03% (4) 
35–44 0.07% (5) 0.17% (13) 0.12% (18) 
45–54 0.15% (8) 0.37% (22) 0.27% (30) 
55–64 0.58% (25) 1.78% (82) 1.19% (107)
65–74 2.31% (69) 5.36% (152) 3.80% (221)
75–84 7.52% (182) 9.70% (167) 8.43% (349)
85+ 12.46% (148) 13.56% (64) 12.77% (212)
Overall 1.08% (438) 1.23% (506) 1.15% (944)
Table 2 Percentage of patients with concurrent cardiovascular diagnoses in people with atrial fibrillation and percentage with 
one or more concurrent diagnoses    
IHD, ischaemic heart disease; HF, heart failure; DM, diabetes mellitus; HT, hypertension; CVA & TIA, cerebrovascular accident or transient ischaemic attack.
 
................................................................................................
Concurrent cardiovascular diagnoses
.......................................................................
No of concurrent diagnoses 
Age group IHD CVA & TIA HF DM HT 1 2 3 4 
Men          
25–34 0 0 0 0 0 0 0 0 0 
35–44 7.7 7.7 0 7.7 15.4 38.5 0 0 0 
45–54 13.6 4.5 9.1 4.5 31.8 40.9 4.5 4.5 0 
55–64 22.0 11.0 7.3 9.8 32.9 26.8 13.4 9.8 0 
65–74 32.9 18.4 15.8 18.4 51.3 37.5 23.0 15.1 2.0 
75–84 34.1 20.4 19.8 16.8 52.1 41.3 26.9 12.0 3.0 
85+ 46.9 21.9 42.2 10.9 46.9 32.8 28.1 20.3 4.7 
All ages 31.6 17.3 18.3 14.5 45.9 36.4 21.9 12.9 2.2 
Women          
25–34 0 0 0 0 0 0 0 0 0 
35–44 0 0 0 0 0 0 0 0 0 
45–54 0 12.5 0 12.5 50.0 37.5 0 12.5 0 
55–64 16.0 8.0 4.0 12.0 32.0 40.0 16.0 0 0 
65–74 15.9 24.6 7.2 15.9 50.7 34.8 24.6 10.1 0 
75–84 27.5 16.5 15.9 13.2 48.9 36.8 22.5 10.4 2.2 
85+ 26.4 20.3 30.4 8.1 49.3 37.2 27.0 8.1 4.7 
All ages 23.7 18.3 18.3 11.6 47.7 36.3 23.3 8.9 2.5 
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The peak age for using Warfarin is between 65 and 74 years
(Table 6) Aspirin is currently prescribed less in men than
women (28.2 and 34.5 per cent, respectively.) Aspirin prescribing
increases as people with AF get older. It is used most in the very
elderly of both sexes. Men have more contraindications to
Warfarin and aspirin recorded than women. 
453 of the 503 men (85.9 per cent) and 351 of 438 (80.1 per
cent) of women diagnosed as having AF are receiving Warfarin
or aspirin or have these drugs contraindicated. The calculation
takes into account that 5 men and 6 women have contraindica-
tions to both Warfarin and aspirin, and that nine additional
men and two women have a code that suggests they have been
advised to purchase their own aspirin ‘OTC’ (over-the-counter
direct from the pharmacist). 
Control of the level of anti-coagulants is measured using
INR with a target range of 2–3. The mean INR for men was
2.46, and for females 2.43. There was no difference in control of
INR across the age groups or between genders. The range was
from 1.0 to 5.8. Approximately a quarter (24.1 per cent) of
those with an INR measure had an out of range result. A total
of 11.3 per cent of men and 9.9 per cent of women had an INR
over 3; and, 14.1 per cent of men and 12.5 per cent of women
had an INR under 2. 
Finally, we looked at high risk26,27 groups to see if more
intensive treatment is being targeted at those most at risk. War-
farin and aspirin were prescribed in similar proportions to
patients in the very high, high and moderate risk categories,
with less prescribed to those at low risk. Men were prescribed
more Warfarin that women, in all three of the highest risk cate-
gories. Hypertension, diabetes and heart failure were more
prevalent in the high risk group; more so than in the very high
risk group (people who had suffered a previous stroke or TIA.)
These diseases were much less prevalent in those at moderate or
low risk. A similar trend was seen in mean blood pressure.
Smoking was most prevalent in the low risk group (Table 7) 
Discussion 
Principal findings 
The study demonstrated that the use of Warfarin remains low,
despite all the evidence of benefit, and guidelines produced for
its use. Where Warfarin is used it is not targeted a those in the
highest risk categories; though overall four out of five patients
with AF are treated with Warfarin or aspirin or have contrain-
dication to these therapies. 
The study showed the feasibility of using computer searches
can be used to identify patients with AF; group them according
to level or risk; and, identify those who are subopitmally man-
aged. Practice computer data was excellent in some areas and
variable in others. Nearly all patients with a diagnosis of AF
Table 3 Percentage of patients with atrial fibrillation who 
have cardiovascular risk factors recorded    
BMI, body mass index (kg/m2); LDL, low density lipoprotein cholesterol.
Age group
Blood 
pressure
Smoking 
status BMI Cholesterol LDL
Men      
25–34 66.7 100.0 33.3 33.3 33.3 
35–44 84.6 69.2 69.2 46.2 23.1 
45–54 100.0 90.9 81.8 40.9 18.2 
55–64 98.8 90.2 91.5 78.0 47.6 
65–74 100.0 90.8 86.2 78.9 53.9
75–84 99.4 91.6 88.6 71.9 40.1 
85+ 95.3 89.1 84.4 57.8 32.8 
All ages 98.4 90.3 86.7 71.0 43.1 
Women      
25–34 100.0 100.0 100.0 0 0 
35–44 100.0 100.0 100.0 40.0 40.0 
45–54 100.0 100.0 87.5 62.5 37.5 
55–64 100.0 96.0 96.0 84.0 36.0 
65–74 100.0 91.3 84.1 68.1 47.8 
75–84 97.8 88.5 89.6 64.8 34.6 
85+ 94.6 79.7 66.9 36.5 16.9 
All ages 97.3% 86.8% 81.5% 56.4% 30.8%
Table 4 Management of cardiovascular risk factors in 
patients with atrial fibrillation    
SD, standard deviation; SE, standard error of the mean; Min, minimum; Max,
maximum. 
Mean SD SE Min Max Median
Men 
Systolic 135.8 17.1 0.8 80.0 190.0 135.0 
Diastolic 77.9 9.8 0.4 50.0 106.0 80.0
BMI 26.8 4.3 0.2 17.2 47.2 26.4
Cholesterol 4.8 0.9 0.0 2.5 9.0 4.8
LDL 2.8 0.8 0.1 1.3 5.5 2.8
Women  
Systolic 138.5 18.3 0.9 90.0 220.0 139.5
Diastolic 77.6 9.3 0.5 50.0 110.0 80.0
BMI 26.2 5.2 0.3 15.2 44.5 25.2
Cholesterol 5.2 1.1 0.1 2.7 8.2 5.1
LDL 2.8 0.8 0.1 1.3 4.8 2.7
Table 5 Percentage with risk factors above intervention 
thresholds    
 
.....................
Men  
....................
Women  
....................
Total  
Blood pressure n % n % N % 
140–149 or 85–89 149 30% 120 27% 269 29% 
≥150 or ≤90 128 25% 136 31% 264 28% 
Total cholesterol    
≥5 mmol/l 64 12.7% 42 9.6% 106 11.3%
LDL-cholesterol    
≥3 mmol/l 47 9.3% 16 3.7% 63 6.7% 
Smoking    
Current smoker 58 11.5% 24 5.5% 82 8.7% 
Ex-smoker 104 20.7% 45 10.3% 149 15.8% 
BMI    
BMI >28 60 11.9% 33 7.5% 93 9.9% 
BMI >30 88 17.5% 74 16.9% 162 17.2% 
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have a record of their blood pressure, smoking habit and BMI;
four out of five have had Warfarin or aspirin prescribed where
it was not contraindicated. However, in others there is consider-
able scope for improvement in practice computer data; particu-
larly the recording of ECG of echocardiograph evidence of left
ventricular hypertrophy. 
We defined the prevalence of AF and how it differs between
the sexes. In men it is at least double that in woman in every ten
year age band up to age 75; after this age prevalence in women
approximates to that in the male population. The overall preva-
lence in males and females is similar because there are many
more women than men alive over age 75. Concurrent cardio-
vascular disease is much more common with advancing age. 
Implications for practice 
The existence of compelling evidence about the benefits of
Warfarin is not translated into practice. The existence of evidence-
based guidance alone is not enough to change practice.18 The rea-
sons why female appear to be prescribed aspirin less often and
Warfarin more often need to be explored. Substantial numbers
would benefit from improved blood pressure control, and possibly
improved monitoring and management of hyperlipidaemia. War-
farin could be better targeted at those at greatest risk of stroke. 
Limitations of the study 
The study is based on routinely collected data, there was no
additional input provided to promote data quality of consist-
ency of recording between practices. 
We did not search the whole general practice record. Only
structured, often referred to as ‘Read coded’ data, were used in
the study. Narrative or ‘free text’ records, including text
scanned into the computer system from hospital letters was not
included. Similarly data still contained within any written
records were not included. 
There was inter-practice variation in data recording, and
where levels of recording were lower than could be reasonably
expected or there was marked variation between practices,
those data were not included. 
We relied on clinician entered codes that Warfarin was
contraindicated, or that there was an adverse reaction; rather than
Table 6 Prescribing and contraindications to Warfarin and aspirin    
 
Prescribed Warfarin
(n)
Percentage
prescribed 
Warfarin 
Warfarin 
contraindicated
(n)
Percentage prescribed or 
contraindicated Warfarin
Male
35–44 1 7.7 0 7.7 
45–54 7 31.8 1 36.4 
55–64 32 39.0 2 41.5 
65–74 85 55.9 8 61.2 
75–84 72 43.1 4 45.5 
85+ 16 25.0 1 26.6 
Total 213 42.6 16 45.8 
Female     
45–54 2 25.0 0 25.0 
55–64 8 32.0 0 32.0 
65–74 31 44.9 2 47.8 
75–84 71 39.0 3 40.7 
85+ 40 27.0 4 29.7 
Total 152 35.2 9 37.3 
Male Prescribed aspirin (n) Percentage
prescribed aspirin
Aspirin 
contraindicated (n)
Percentage prescribed or 
contraindicated aspirin
35–44 2 12.5 1 18.8 
45–54 1 4.5 0 4.5 
55–64 21 25.6 12 40.2 
65–74 33 21.7 27 39.5 
75–84 54 32.3 29 49.7 
85+ 31 48.4 8 60.9 
Total 142 28.2 77 43.5 
Female     
45–54 1 12.5 1 25.0 
55–64 5 20.0 1 24.0 
65–74 19 27.5 7 37.7 
75–84 60 33.0 24 46.2 
85+ 64 43.2 12 51.4 
Total 149 34.5 45 44.9 
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following the example of Carroll and Majeed6 and actively search-
ing for data that identified that a contraindication was present. 
It was not possible to separate those patients who have parox-
ysmal AF, from those with persistent; nor was there consistent
data recorded about cardioversion or carotid endarterectomy. 
We acknowledged within our method that there are subtle
variations between the different computer manufacturers’
coding of data, and that we had to arbitrarily define what repre-
sented ‘current’ therapy. 
Comparison with the literature 
The age standardized prevalence of AF: 7.36 per cent in the
over 65s, and 12.3 per cent in the over 85s (crude rates are 6 and
12 per cent) is higher than the 5 and 10 per cent reported else-
where.5,6 Though similar to that reported in 1998.3 The area
from which the data in this study is collected is one of relatively
high social class, something known to be associated with lower
levels of cardiac morbidity.29,30 This data might indicate that
the prevalence of AF is continuing to rise.3,4 
This data shows much higher rates of anticoagulant use in
routine clinical practice than in previous studies. It is roughly
double the level (22 per cent) found by Deplanque et al.,16 and
that (21 per cent) found by Wheeldon et al.,31 and Sudlow
et al.32 (23 per cent). Practice based, near patient anti-coagulant
monitoring may contribute towards more patients to be treated
with Warfarin.33 The difference between male and female
treatment rates might be that men are started on Warfarin in
secondary care when treated for their heart disease or other car-
diovascular morbidity at a younger age. 
People with AF would benefit from further reduction in
blood pressure:8 
‘. . . each 10 mmHg lower systolic BP is associated with a
decrease in risk of stroke of approximately one third in subjects
aged 60 to 79 years. The association is continuous down to
levels of at least 115/75 mmHg. . . .’ 
Call for further research 
Examination of the complete medical record, computerized and
written, would allow the validity of these findings to be
checked; there are well established methods to do this.34,35 
The reasons for inter-practice variability in data need to be
better understood; although reported for more than 10 years36
they persist in many clinical areas.37,38 
We need to know what type of intervention is likely to be
successful in changing the behaviour of clinicians and ensure
best practice is implemented. This might include use of: educa-
tion,37 telemedicine,39 near patient testing,33 financial incentives
or other approach to improve the quality of care. 
Conclusions 
Usage of Warfarin remains low despite the existence of evidence
and guidance for its use; though the practices involved in this
study are achieving higher levels of anti-coagulant monitoring
than previously reported. Use of Warfarin does not appear to be
targeted at those at highest risk. Priorities for practices and locali-
ties should be: improved uptake of Warfarin for people with AF
of high and very high risk of stroke; and, improved management
of blood pressure. Automated searches of computer data have
allowed subopitmally managed patients with AF to be identified;
so that they can benefit from improved quality of care. 
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